Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. WO2019106572 - COMPOSITION POUR TRAITER ET PRÉVENIR LE DIABÈTE SUCRÉ DE TYPE II ET LA MALADIE D'ALZHEIMER

Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

[ EN ]

CLAIMS

1 A composition comprising:

the compound of Formula II and/or a salt thereof


Formula II

where:

Ri, R2, R7, and Rx are each independently hydrogen, alkyl, or -COR9, where R9 is an alkyl group, a substituted alkyl group, an aryl group, or a substituted aryl group;

R3, R4, R5 are each independently H, =0, or OR10 where Rio is hydrogen, an alkyl group, a substituted alkyl group, aryl group, or a substitute aryl group; and R6 is a disubstituted hydrocarbon ring having at least 6 carbon atoms.

2. The composition of claim 1, wherein the composition comprises 15 to 99.9% by weight of the compound of Formula II.

3. The composition of any of claims 1 to 2, wherein the composition does not comprise a second anti-diabetes agent.

4. The composition of any one of claims 1 to 2, wherein the composition further comprises at least one second anti-diabetes agent.

5. The composition of claim 4, wherein the at least one second anti-diabetes agent is an anti-diabetes mellitus type II agent.

6. The composition of claim 5, wherein the anti-diabetes mellitus type II agent is metformin, glimepiride, glyburide, glipizide, repaglinide, nateglinide, pioglitazone, sitagliptin, saxagliptin, linagliptin, acarbose, miglitol, colesevelam, insulin, or salts thereof, or any combination thereof.

7. The composition of any one of claims 1 to 6, wherein the composition is formulated for oral administration.

8. The composition of claim 7, wherein the composition is one or more of a lozenge, a powder, a tablet, a gel-cap, a delayed release capsule, a quick release capsule, a gelatin, a liquid solution, and/or a dissolvable film.

9. The composition of any one of claims 1 to 8, wherein the composition is formulated for topical application, intravenous administration, subcutaneous administration, intramuscular administration, and/or intranasal delivery.

10. The composition of any one of claims 1 to 8, wherein the compound of Formula II is the compound of Formula I


Formula I

and/or a salt thereof.

11. The composition of any one of claims 1 to 8, wherein the compound of Formula II is the compound of Formula III


Formula III

and/or a salt thereof.

12. The composition of any one of claims 1 to 8, wherein the compound of Formula II is the compound of Formula IV


Formula IV

and/or a salt thereof.

13. The composition of any one of claims 1 to 8, wherein the compound of Formula II is the compound of Formula V


Formula V

and/or a salt thereof.

14. The composition of any one of claims 1 to 8, wherein the compound of Formula II is the compound of Formula VI


Formula VI

and/or a salt thereof.

15. A method of treating a subject with diabetes mellitus type II or at risk of diabetes mellitus type II, the method comprising administering to the subject a compound of Formula II and/or a salt thereof


Formula II

where:

Ri, R2, R7, and Rx are each independently hydrogen, alkyl, or -COR9, where R9 is an alkyl group, a substituted alkyl group, an aryl group, or a substituted aryl group;

R3, R4, R5 are each independently H, =0, or OR10 where Rio is hydrogen, an alkyl group, a substituted alkyl group, aryl group, or a substitute aryl group; and R6 is a disubstituted hydrocarbon ring having at least 6 carbon atoms.

16. The method of claim 15, wherein the subject has diabetes mellitus type II.

17. The method of claim 15, wherein the subject has metabolic syndrome and/or pre-diabetes.

18. The method of any one of claims 15 to 17, wherein the subject is administered a total sum of between 0.1 and 10,000 mg, preferably between 1 and 1,500 mg, between 5 and 1,000 mg, or between 10 and 500 mg of the compound of Formula II during a 24 hour period.

19. The method of any one of claims 15 to 18, wherein the composition is administered at least once a day for at least five days.

20. The method of any one of claims 15 to 19, wherein the compound of Formula II that is administered to the subject is the compound of Formula I


Formula I

and/or a salt thereof.

21. The method of any one of claims 15 to 19, wherein the compound of Formula II that is administered to the subject is the compound of Formula III


Formula III

and/or a salt thereof.

22. The method of any one of claims 15 to 19, wherein the compound of Formula II that is administered to the subject is the compound of Formula IV


Formula IV

and/or a salt thereof.

23. The method of any one of claims 15 to 19, wherein the compound of Formula II that is administered to the subject is the compound of Formula V


Formula V

and/or a salt thereof.

24. The method of any one of claims 15 to 19, wherein the compound of Formula II that is administered to the subject is the compound of Formula VI


Formula VI

and/or a salt thereof.

25. A method of preventing diabetes mellitus type II in a subject, the method comprising administering to the subject a compound of Formula II and/or a salt thereof


Formula II

where:

Ri, R2, R7, and Rx are each independently hydrogen, alkyl, or -COR9, where R9 is an alkyl group, a substituted alkyl group, an aryl group, or a substituted aryl group;

R3, R4, R5 are each independently H, =0, or OR10 where Rio is hydrogen, an alkyl group, a substituted alkyl group, aryl group, or a substitute aryl group; and R6 is a disubstituted hydrocarbon ring having at least 6 carbon atoms,

wherein diabetes mellitus type II is prevented in the subject.

26. The method of claim 25, wherein the subject has metabolic syndrome.

27. The method of claim 25, wherein the subject has pre-diabetes.

28. The method of any one of claims 25 to 27, wherein the subject is administered a total sum of between 0.1 and 10,000 mg, preferably between 1 and 1,500 mg, between 5 and 1,000 mg, or between 10 and 500 mg of the compound of Formula II during a 24 hour period.

29. The method of any one of claims 25 to 28, wherein the composition is administered at least once a day for at least five days.

30. The method of any one of claims 25 to 29, wherein the compound of Formula II that is administered to the subject is the compound of Formula III


Formula I

and/or a salt thereof.

31. The method of any one of claims 25 to 29, wherein the compound of Formula II that is administered to the subject is the compound of Formula III


Formula III

and/or a salt thereof.

32. The method of any one of claims 25 to 29, wherein the compound of Formula II that is administered to the subject is the compound of Formula IV


Formula IV

and/or a salt thereof.

33. The method of any one of claims 25 to 29, wherein the compound of Formula II that is administered to the subject is the compound of Formula V


Formula V

and/or a salt thereof.

34. The method of any one of claims 25 to 29, wherein the compound of Formula II that is administered to the subject is the compound of Formula VI


Formula VI

and/or a salt thereof.

35. A method of reducing aggregation of islet amyloid polypeptide, the method comprising contacting islet amyloid polypeptide with a compound of Formula II and/or a salt thereof


Formula II

where:

Ri, R2, R7, and Rx are each independently hydrogen, alkyl, or -COR9, where R9 is an alkyl group, a substituted alkyl group, an aryl group, or a substituted aryl group;

R3, R4, R5 are each independently H, =0, or OR10 where Rio is hydrogen, an alkyl group, a substituted alkyl group, aryl group, or a substitute aryl group; and R6 is a disubstituted hydrocarbon ring having at least 6 carbon atoms,

wherein aggregation of islet amyloid polypeptide is reduced.

36. The method of claim 35, wherein the compound of Formula II is administered to a subject.

37. The method of claim 36, wherein the subject has diabetes mellitus type II.

38. The method of claim 36, wherein the subject has metabolic syndrome.

39. The method of claim 36, wherein the subject has pre-diabetes.

40. The method of any one of claims 36 to 39, wherein the subject is administered a total sum of between 0.1 and 10,000 mg, preferably between 1 and 1,500 mg, between 5 and 1,000 mg, or between 10 and 500 mg of the compound of formula II during a 24 hour period.

41. The method of any one of claims 36 to 40, wherein the composition is administered at least once a day for at least five days.

42. The method of any one of claims 35 to 41, wherein the compound of Formula II that contacts islet amyloid polypeptide is the compound of Formula III


Formula I

and/or a salt thereof.

43. The method of any one of claims 35 to 41, wherein the compound of Formula II that contacts islet amyloid polypeptide is the compound of Formula III


Formula III

and/or a salt thereof.

44. The method of any one of claims 35 to 41, wherein the compound of Formula II that contacts islet amyloid polypeptide is the compound of Formula IV


Formula IV

and/or a salt thereof.

45. The method of any one of claims 35 to 41, wherein the compound of Formula II that contacts islet amyloid polypeptide is the compound of Formula V


Formula V

and/or a salt thereof.

46. The method of any one of claims 35 to 41, wherein the compound of Formula II that contacts islet amyloid polypeptide is the compound of Formula VI


Formula VI

and/or a salt thereof.